QGENNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
QIAGEN N.V.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026
$46.55+0.42 (+0.91%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 24.0
- Dividend yield
- 0.54%
Share price
−$4.26 (−8.39%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Ex-dividend
QIAGEN N.V. grew revenue 5.7% to $2.09B over fiscal 2025. Operating income rose 376.8% to $465.85M, moving the operating margin from 4.9% to 22.3%. Free cash flow was $453.28M, down 10.5% from a year earlier.
Revenue
$2.09B
+5.7% vs. a year earlier
Operating income
$465.85M
+376.8% vs. a year earlier
Free cash flow
$453.28M
-10.5% vs. a year earlier
EPS, diluted
$1.94
+424.3% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Dec 31, 2025
Valuation
- Market cap
- –
- P/E ratio
- 24.0
- Price to sales
- –
- Price to book
- –
- Dividend yield
- 0.54%
- Free cash flow yield
- –
Fundamentals
- Revenue
- $2.09B
- Net income
- $424.88M
- EPS, diluted
- $1.94
- Free cash flow
- $453.28M
Fifteen years at a glance
Fiscal years 2011 to 2025, USD
Revenue
$2.09B+5.7% YoY
Gross profit
$1.30B+34.3% YoY
Operating income
$465.85M+376.8% YoY
Net income
$424.88M+408.3% YoY
EPS, diluted
$1.94+424.3% YoY
Free cash flow
$453.28M-10.5% YoY
Reported period